Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lu AG09222 Safety and PK/PD in Allergic Rhinitis
NCT05126316Phase 1Completed
- Sponsor
- Lundbeck
- Start
- Nov 2021
- Primary completion
- Jul 2022
- Modality
- IgG Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of lu ag09222 in allergic rhinitis (AR) (3 arms), sponsored by Lundbeck. Primary endpoint: Number of Participants With Adverse Events. Started Nov 2021; status: completed.
02
Drugs
lu ag09222
03
Conditions
allergic rhinitis (AR)
Beyond the preview
Go deeper on NCT05126316.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05126316.